| 2026-02-09 Filed 2026-02-09 | Howze Yalonda Officer: INTERIM CEO AND PRESIDENT | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | Disposed (D) | 3,759 | — | — | 0 | Direct (D) | No | F1, F2 - F1 Pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), by and among Generation Bio. Co. (the Issuer), XOMA Royalty Corporation (Parent) and Parent's wholly-owned subsidiary, XRA 7 Corp. (Merger Sub), dated as of December 15, 2025, the shares (the Shares) of common stock, par value $0.0001 per share, of the Issuer (the Common Stock) that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the Cash Amount), plus (ii) one non-tradeable contingent value right per Share (the CVR),
- F2 (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the Offer Price). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the Effective Time), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
| Open filing 0001104659-26-012190 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Howze Yalonda Officer: INTERIM CEO AND PRESIDENT | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (10,710) — exercise price 39.70 | Disposed (D) | 10,710 | — | — | 0 | Direct (D) | No | F3 - F3 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
| Open filing 0001104659-26-012190 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Howze Yalonda Officer: INTERIM CEO AND PRESIDENT | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (11,883) — exercise price 18.60 | Disposed (D) | 11,883 | — | — | 0 | Direct (D) | No | F3 - F3 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
| Open filing 0001104659-26-012190 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Howze Yalonda Officer: INTERIM CEO AND PRESIDENT | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (25,102) — exercise price 9.255 | Disposed (D) | 25,102 | — | — | 0 | Direct (D) | No | F3 - F3 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
| Open filing 0001104659-26-012190 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Howze Yalonda Officer: INTERIM CEO AND PRESIDENT | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (7,630) — exercise price 13.90 | Disposed (D) | 7,630 | — | — | 0 | Direct (D) | No | F3 - F3 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
| Open filing 0001104659-26-012190 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Appelhans Dannielle Director | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | Disposed (D) | 1,263 | — | — | 0 | Direct (D) | No | F1, F2 - F1 Pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), by and among Generation Bio. Co. (the Issuer), XOMA Royalty Corporation (Parent) and Parent's wholly-owned subsidiary, XRA 7 Corp. (Merger Sub), dated as of December 15, 2025, the shares (the Shares) of common stock, par value $0.0001 per share, of the Issuer (the Common Stock) that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the Cash Amount), plus (ii) one non-tradeable contingent value right per Share (the CVR),
- F2 (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the Offer Price). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the Effective Time), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
| Open filing 0001104659-26-012182 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Appelhans Dannielle Director | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | Disposed (D) | 736 | — | — | 0 | Indirect (I) By Spouse | No | F1, F2 - F1 Pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), by and among Generation Bio. Co. (the Issuer), XOMA Royalty Corporation (Parent) and Parent's wholly-owned subsidiary, XRA 7 Corp. (Merger Sub), dated as of December 15, 2025, the shares (the Shares) of common stock, par value $0.0001 per share, of the Issuer (the Common Stock) that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the Cash Amount), plus (ii) one non-tradeable contingent value right per Share (the CVR),
- F2 (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the Offer Price). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the Effective Time), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
| Open filing 0001104659-26-012182 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Appelhans Dannielle Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (3,000) — exercise price 3.874 | Disposed (D) | 3,000 | — | — | 0 | Direct (D) | No | F3 - F3 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (Issuer Option) that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an In-The-Money Option), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time.
| Open filing 0001104659-26-012182 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Appelhans Dannielle Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (3,840) — exercise price 71.80 | Disposed (D) | 3,840 | — | — | 0 | Direct (D) | No | F4 - F4 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
| Open filing 0001104659-26-012182 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Appelhans Dannielle Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (2,500) — exercise price 48.30 | Disposed (D) | 2,500 | — | — | 0 | Direct (D) | No | F4 - F4 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
| Open filing 0001104659-26-012182 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Appelhans Dannielle Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (6,000) — exercise price 33.20 | Disposed (D) | 6,000 | — | — | 0 | Direct (D) | No | F4 - F4 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
| Open filing 0001104659-26-012182 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Conway Kevin John Officer: CHIEF FINANCIAL OFFICER | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | Disposed (D) | 2,072 | — | — | 0 | Direct (D) | No | F1, F2 - F1 Pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), by and among Generation Bio. Co. (the Issuer), XOMA Royalty Corporation (Parent) and Parent's wholly-owned subsidiary, XRA 7 Corp. (Merger Sub), dated as of December 15, 2025, the shares (the Shares) of common stock, par value $0.0001 per share, of the Issuer (the Common Stock) that were tendered to Merger Sub prior to the expiration time of the Offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the Cash Amount), plus (ii) one non-tradeable contingent value right per Share (the CVR),
- F2 (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the Offer Price). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the Effective Time), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
| Open filing 0001104659-26-012188 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Conway Kevin John Officer: CHIEF FINANCIAL OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (1,192) — exercise price 63.587 | Disposed (D) | 1,192 | — | — | 0 | Direct (D) | No | F3 - F3 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
| Open filing 0001104659-26-012188 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Conway Kevin John Officer: CHIEF FINANCIAL OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (283) — exercise price 51.576 | Disposed (D) | 283 | — | — | 0 | Direct (D) | No | F3 - F3 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
| Open filing 0001104659-26-012188 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Conway Kevin John Officer: CHIEF FINANCIAL OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (1,061) — exercise price 190.00 | Disposed (D) | 1,061 | — | — | 0 | Direct (D) | No | F3 - F3 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
| Open filing 0001104659-26-012188 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Conway Kevin John Officer: CHIEF FINANCIAL OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (621) — exercise price 302.50 | Disposed (D) | 621 | — | — | 0 | Direct (D) | No | F3 - F3 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
| Open filing 0001104659-26-012188 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Conway Kevin John Officer: CHIEF FINANCIAL OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (1,399) — exercise price 316.90 | Disposed (D) | 1,399 | — | — | 0 | Direct (D) | No | F3 - F3 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
| Open filing 0001104659-26-012188 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Conway Kevin John Officer: CHIEF FINANCIAL OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (2,585) — exercise price 64.90 | Disposed (D) | 2,585 | — | — | 0 | Direct (D) | No | F3 - F3 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
| Open filing 0001104659-26-012188 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Conway Kevin John Officer: CHIEF FINANCIAL OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (2,800) — exercise price 81.80 | Disposed (D) | 2,800 | — | — | 0 | Direct (D) | No | F3 - F3 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
| Open filing 0001104659-26-012188 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Conway Kevin John Officer: CHIEF FINANCIAL OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (5,940) — exercise price 18.60 | Disposed (D) | 5,940 | — | — | 0 | Direct (D) | No | F3 - F3 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
| Open filing 0001104659-26-012188 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Conway Kevin John Officer: CHIEF FINANCIAL OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (200) — exercise price 42.90 | Disposed (D) | 200 | — | — | 0 | Direct (D) | No | F3 - F3 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
| Open filing 0001104659-26-012188 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Conway Kevin John Officer: CHIEF FINANCIAL OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (249) — exercise price 31.60 | Disposed (D) | 249 | — | — | 0 | Direct (D) | No | F3 - F3 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
| Open filing 0001104659-26-012188 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Conway Kevin John Officer: CHIEF FINANCIAL OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (35,525) — exercise price 9.255 | Disposed (D) | 35,525 | — | — | 0 | Direct (D) | No | F3 - F3 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
| Open filing 0001104659-26-012188 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Conway Kevin John Officer: CHIEF FINANCIAL OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (1,877) — exercise price 47.05 | Disposed (D) | 1,877 | — | — | 0 | Direct (D) | No | F3 - F3 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
| Open filing 0001104659-26-012188 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Conway Kevin John Officer: CHIEF FINANCIAL OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (550) — exercise price 50.60 | Disposed (D) | 550 | — | — | 0 | Direct (D) | No | F3 - F3 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
| Open filing 0001104659-26-012188 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Conway Kevin John Officer: CHIEF FINANCIAL OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (1,763) — exercise price 13.90 | Disposed (D) | 1,763 | — | — | 0 | Direct (D) | No | F3 - F3 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
| Open filing 0001104659-26-012188 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Stehman-Breen Catherine Director | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | Disposed (D) | 4,752 | — | — | 0 | Direct (D) | No | F1, F2 - F1 Pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), by and among Generation Bio. Co. (the Issuer), XOMA Royalty Corporation (Parent) and Parent's wholly-owned subsidiary, XRA 7 Corp. (Merger Sub), dated as of December 15, 2025, the shares (the Shares) of common stock, par value $0.0001 per share, of the Issuer (the Common Stock) that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the Cash Amount), plus (ii) one non-tradeable contingent value right per Share (the CVR),
- F2 (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the Offer Price). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the Effective Time), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
| Open filing 0001104659-26-012197 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Stehman-Breen Catherine Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (3,000) — exercise price 3.874 | Disposed (D) | 3,000 | — | — | 0 | Direct (D) | No | F3 - F3 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (Issuer Option) that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an In-The-Money Option), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time.
| Open filing 0001104659-26-012197 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Stehman-Breen Catherine Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (5,200) — exercise price 190.00 | Disposed (D) | 5,200 | — | — | 0 | Direct (D) | No | F4 - F4 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
| Open filing 0001104659-26-012197 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Stehman-Breen Catherine Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (1,500) — exercise price 265.90 | Disposed (D) | 1,500 | — | — | 0 | Direct (D) | No | F4 - F4 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
| Open filing 0001104659-26-012197 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Stehman-Breen Catherine Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (1,920) — exercise price 61.90 | Disposed (D) | 1,920 | — | — | 0 | Direct (D) | No | F4 - F4 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
| Open filing 0001104659-26-012197 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Stehman-Breen Catherine Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (2,500) — exercise price 48.30 | Disposed (D) | 2,500 | — | — | 0 | Direct (D) | No | F4 - F4 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
| Open filing 0001104659-26-012197 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Stehman-Breen Catherine Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (6,000) — exercise price 33.20 | Disposed (D) | 6,000 | — | — | 0 | Direct (D) | No | F4 - F4 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
| Open filing 0001104659-26-012197 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Rhodes Jason P Director | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | Disposed (D) | 711,193 | — | — | 0 | Indirect (I) See Footnote | No | F1, F2, F3 - F1 Pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), by and among Generation Bio. Co. (the Issuer), XOMA Royalty Corporation (Parent) and Parent's wholly-owned subsidiary, XRA 7 Corp. (Merger Sub), dated as of December 15, 2025, the shares (the Shares) of common stock, par value $0.0001 per share, of the Issuer (the Common Stock) that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the Cash Amount), plus (ii) one non-tradeable contingent value right per Share (the CVR),
- F2 (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the Offer Price). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the Effective Time), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
- F3 The shares are held directly by Atlas Venture Fund X, L.P. (Atlas Venture Fund X). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. (AVA X LP). Atlas Venture Associates X, LLC (AVA X LLC) is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any.
| Open filing 0001104659-26-012195 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Rhodes Jason P Director | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | Disposed (D) | 116,693 | — | — | 0 | Indirect (I) See Footnote | No | F1, F2, F4 - F1 Pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), by and among Generation Bio. Co. (the Issuer), XOMA Royalty Corporation (Parent) and Parent's wholly-owned subsidiary, XRA 7 Corp. (Merger Sub), dated as of December 15, 2025, the shares (the Shares) of common stock, par value $0.0001 per share, of the Issuer (the Common Stock) that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the Cash Amount), plus (ii) one non-tradeable contingent value right per Share (the CVR),
- F2 (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the Offer Price). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the Effective Time), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
- F4 The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. (AVOF I). Atlas Venture Associates Opportunity I, L.P. (AVAO LP) is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC (AVAO LLC) is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of his pecuniary interest therein, if any.
| Open filing 0001104659-26-012195 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Rhodes Jason P Director | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | Disposed (D) | 60 | — | — | 0 | Indirect (I) See Footnote | No | F1, F2, F5 - F1 Pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), by and among Generation Bio. Co. (the Issuer), XOMA Royalty Corporation (Parent) and Parent's wholly-owned subsidiary, XRA 7 Corp. (Merger Sub), dated as of December 15, 2025, the shares (the Shares) of common stock, par value $0.0001 per share, of the Issuer (the Common Stock) that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the Cash Amount), plus (ii) one non-tradeable contingent value right per Share (the CVR),
- F2 (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the Offer Price). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the Effective Time), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
- F5 The shares are held directly by Atlas Venture Associates Opportunity I, L.P. (AVAO LP). Atlas Venture Associates Opportunity I, LLC (AVAO LLC) is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of the securities held by AVAO LP, except to the extent of his pecuniary interest therein, if any.
| Open filing 0001104659-26-012195 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Rhodes Jason P Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (3,000) — exercise price 3.874 | Disposed (D) | 3,000 | — | — | 0 | Direct (D) | No | F6 - F6 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (Issuer Option) that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an In-The-Money Option), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time.
| Open filing 0001104659-26-012195 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Rhodes Jason P Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (5,200) — exercise price 190.00 | Disposed (D) | 5,200 | — | — | 0 | Direct (D) | No | F7 - F7 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
| Open filing 0001104659-26-012195 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Rhodes Jason P Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (1,500) — exercise price 265.90 | Disposed (D) | 1,500 | — | — | 0 | Direct (D) | No | F7 - F7 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
| Open filing 0001104659-26-012195 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Rhodes Jason P Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (1,920) — exercise price 61.90 | Disposed (D) | 1,920 | — | — | 0 | Direct (D) | No | F7 - F7 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
| Open filing 0001104659-26-012195 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Rhodes Jason P Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (2,500) — exercise price 48.30 | Disposed (D) | 2,500 | — | — | 0 | Direct (D) | No | F7 - F7 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
| Open filing 0001104659-26-012195 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Rhodes Jason P Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (6,000) — exercise price 33.20 | Disposed (D) | 6,000 | — | — | 0 | Direct (D) | No | F7 - F7 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
| Open filing 0001104659-26-012195 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Atlas Venture Fund X, L.P. 10% ownerATLAS VENTURE ASSOCIATES X, L.P. 10% ownerAtlas Venture Associates X, LLC 10% ownerAtlas Venture Opportunity Fund I, L.P. 10% ownerAtlas Venture Associates Opportunity I, L.P. 10% ownerAtlas Venture Associates Opportunity I, LLC 10% owner | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | Disposed (D) | 711,193 | — | — | 0 | Direct (D) | No | F1, F2, F3 - F1 Pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), by and among Generation Bio. Co. (the Issuer), XOMA Royalty Corporation (Parent) and Parent's wholly-owned subsidiary, XRA 7 Corp. (Merger Sub), dated as of December 15, 2025, the shares (the Shares) of common stock, par value $0.0001 per share, of the Issuer (the Common Stock) that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per
Share to the stockholders in cash, without interest and less any applicable tax withholding (the Cash Amount), plus (ii) one non-tradeable contingent value right per Share (the CVR),
- F2 (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the Offer Price). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer,
effective as of February 9, 2026 (the Effective Time), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
- F3 The shares are held directly by Atlas Venture Fund X, L.P. (Atlas Venture Fund X). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. (AVA X LP). Atlas Venture Associates X, LLC (AVA X LLC) is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any.
| Open filing 0001231919-26-000124 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Atlas Venture Fund X, L.P. 10% ownerATLAS VENTURE ASSOCIATES X, L.P. 10% ownerAtlas Venture Associates X, LLC 10% ownerAtlas Venture Opportunity Fund I, L.P. 10% ownerAtlas Venture Associates Opportunity I, L.P. 10% ownerAtlas Venture Associates Opportunity I, LLC 10% owner | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | Disposed (D) | 116,693 | — | — | 0 | Indirect (I) See footnote | No | F1, F2, F4 - F1 Pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), by and among Generation Bio. Co. (the Issuer), XOMA Royalty Corporation (Parent) and Parent's wholly-owned subsidiary, XRA 7 Corp. (Merger Sub), dated as of December 15, 2025, the shares (the Shares) of common stock, par value $0.0001 per share, of the Issuer (the Common Stock) that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per
Share to the stockholders in cash, without interest and less any applicable tax withholding (the Cash Amount), plus (ii) one non-tradeable contingent value right per Share (the CVR),
- F2 (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the Offer Price). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer,
effective as of February 9, 2026 (the Effective Time), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
- F4 The shares are held directly by Atlas Venture Opportunity Fund I, L.P. (Atlas Venture Opportunity Fund I). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, LP (AVAO I LP). Atlas Venture Associates Opportunity I, LLC (AVAO I LLC) is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.
| Open filing 0001231919-26-000124 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Atlas Venture Fund X, L.P. 10% ownerATLAS VENTURE ASSOCIATES X, L.P. 10% ownerAtlas Venture Associates X, LLC 10% ownerAtlas Venture Opportunity Fund I, L.P. 10% ownerAtlas Venture Associates Opportunity I, L.P. 10% ownerAtlas Venture Associates Opportunity I, LLC 10% owner | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | Disposed (D) | 60 | — | — | 0 | Indirect (I) See footnote | No | F1, F2, F5 - F1 Pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), by and among Generation Bio. Co. (the Issuer), XOMA Royalty Corporation (Parent) and Parent's wholly-owned subsidiary, XRA 7 Corp. (Merger Sub), dated as of December 15, 2025, the shares (the Shares) of common stock, par value $0.0001 per share, of the Issuer (the Common Stock) that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per
Share to the stockholders in cash, without interest and less any applicable tax withholding (the Cash Amount), plus (ii) one non-tradeable contingent value right per Share (the CVR),
- F2 (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the Offer Price). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer,
effective as of February 9, 2026 (the Effective Time), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
- F5 The shares are held directly by AVAO I LP. AVAO I LLC is the general partner of AVAO I LP. AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVAO I LP except to the extent of its pecuniary interest therein, if any.
| Open filing 0001231919-26-000124 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Quinn Anthony G. Director | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | Disposed (D) | 29,928 | — | — | 0 | Direct (D) | No | F1, F2 - F1 Pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), by and among Generation Bio. Co. (the Issuer), XOMA Royalty Corporation (Parent) and Parent's wholly-owned subsidiary, XRA 7 Corp. (Merger Sub), dated as of December 15, 2025, the shares (the Shares) of common stock, par value $0.0001 per share, of the Issuer (the Common Stock) that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the Cash Amount), plus (ii) one non-tradeable contingent value right per Share (the CVR),
- F2 (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the Offer Price). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the Effective Time), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
| Open filing 0001104659-26-012194 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Quinn Anthony G. Director | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | Disposed (D) | 7,283 | — | — | 0 | Indirect (I) By Quinn Family Irrevocable Trust of 2021 | No | F1, F2, F3 - F1 Pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), by and among Generation Bio. Co. (the Issuer), XOMA Royalty Corporation (Parent) and Parent's wholly-owned subsidiary, XRA 7 Corp. (Merger Sub), dated as of December 15, 2025, the shares (the Shares) of common stock, par value $0.0001 per share, of the Issuer (the Common Stock) that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the Cash Amount), plus (ii) one non-tradeable contingent value right per Share (the CVR),
- F2 (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the Offer Price). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the Effective Time), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
- F3 The securities are directly held by the Quinn Family Irrevocable Trust of 2021 (the Quinn Family Trust), formerly the Spousal Lifetime Access Trust. Anthony G. Quinn is the settlor of the Quinn Family Trust, M. Clare Quinn is the trustee for the Quinn Family Trust and the Quinn Family Trust is for the benefit of M. Clare Quinn, Emma, Richard, and Charles Quinn.
| Open filing 0001104659-26-012194 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Quinn Anthony G. Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (3,000) — exercise price 3.874 | Disposed (D) | 3,000 | — | — | 0 | Direct (D) | No | F4 - F4 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (Issuer Option) that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an In-The-Money Option), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time.
| Open filing 0001104659-26-012194 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Quinn Anthony G. Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (5,200) — exercise price 190.00 | Disposed (D) | 5,200 | — | — | 0 | Direct (D) | No | F5 - F5 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
| Open filing 0001104659-26-012194 Read from the filing’s XML Dispute this row |
| 2026-02-09 Filed 2026-02-09 | Quinn Anthony G. Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (1,500) — exercise price 265.90 | Disposed (D) | 1,500 | — | — | 0 | Direct (D) | No | F5 - F5 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
| Open filing 0001104659-26-012194 Read from the filing’s XML Dispute this row |